A
Alcista
Alcista · 25%SMMT
$32.18
Precio del escenario
$14.500
-0.909 (-6.27%)Al cierre
Loading chart…
- Máximo
- 15.615
- Apertura
- 15.490
- Precio medio ponderado por volumen
- 14.83
- Volumen
- 4.78M
- Capitalización
- 5.52B
- Mínimo
- 14.370
- Importe
- 70.92M
- EV/EBITDA, TTM
- 0.00
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Análisis de IA of Summit Therapeutics Inc (SMMT)
ComprarSummit Therapeutics Inc is a good buy right now due to its recent $2 billion investment from AstraZeneca, which provides a significant funding boost and a target price of $18.36 per share, representing a 19% premium over the current price of $15.47. Additionally, the forward P/E ratio of 3.72 indicates potential for growth compared to its current valuation. The main risk is the company's ongoing negative earnings, with an EPS estimate of -0.28 for the next quarter, which could impact investor sentiment if results do not meet expectations.
Recomendaciones de analistas (6)
+193.03% de potencial alcista
Comprar
6 Comprar
0 Mantener
0 Vender
Actual: 14.50
Mínimo
18.00
Promedio
42.49
Máximo
131.90
Barclays
Equal Weight
$20
2026-10-01
Barclays
2026-10-01
Precio objetivo
$20
Equal Weight
Citi
Comprar
$43
2026-09-29
Citi
2026-09-29
Precio objetivo
$43
Comprar
Jefferies
Comprar
$25
2026-09-09
Jefferies
2026-09-09
Precio objetivo
$25
Comprar
Bernstein
Market Perform
—
2026-08-25
Bernstein
2026-08-25
Precio objetivo
—
Market Perform
Leerink
Market Perform
$13
2026-08-12
Leerink
2026-08-12
Precio objetivo
$13
Market Perform
Métricas de valoración
El PER previsto actual de Summit Therapeutics Inc (SMMT) es 3.72, frente a su media de 5 años de -20.32.
Escenarios de precio de Alphio AI para SMMT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SMMT en cartera
Cronología de eventos
Noticias
9.010-25NewsfilterFirst Regimen to Significantly Improve Survival in Biliary Tract Cancer
7.510-24PRnewswireLunit Partners with Summit for AI Pathology Research
- 7.510-24Newsfilter
Lunit and Summit Announce Research Agreement for AI Pathology in Immuno-Oncology
- 7.510-23Newsfilter
Summit and Lunit Announce Research Agreement for AI Pathology Analysis
- 9.010-22Newsfilter
Ivonescimab Clinical Data to Feature at ESMO 2026
Preguntas frecuentes sobre SMMT, respondidas por Alphio AI
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Summit Therapeutics Inc is a good buy right now due to its recent $2 billion investment from AstraZeneca, which provides a significant funding boost and a target price of $18.36 per share, representing a 19% premium over the current price of $15.47. Additionally, the forward P/E ratio of 3.72 indicates potential for growth compared to its current valuation. The main risk is the company's ongoing negative earnings, with an EPS estimate of -0.28 for the next quarter, which could impact investor sentiment if results do not meet expectations.
6 analysts cover SMMT: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 42.49.
Comunidad
Más ↗
Trading Gap & Crap Short Setup _ $NVTS & $SMMT Watch this video to see the setup and understand the strategy. 🎯
Mostrar más
$SMMT just landed a major combo opportunity for ivonescimab — and Datroway is the key. Summit is teaming with AstraZeneca ($AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway, a TROP2-targeted ADC jointly developed and commercialized by Daiichi and AstraZeneca. The initial focus is a Phase III study in first-line TNBC, while the collaboration plans to evaluate the combo across multiple solid tumors, including breast and lung cancers. Latest SMMT news here
Mostrar más
$SMMT $AZN Citi raised its price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from AstraZeneca (AZN). AstraZeneca's $2B investment in convertible preferred shares is equivalent to $18.36 per common share, representing a 19% premium to Summit's latest closing price, the analyst tells investors in a research note. Citi views the deal as a "de-risking event" that removes Summit's financing overhang.
Mostrar más
$SMMT is up 20% after hours on a $2B investment from $AZN. These big January call spreads are still in the OI.
Mostrar más
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.